-
Innovation Ranking
NewInnovation Ranking – Halozyme Therapeutics Inc
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded recombinant formulation of rHuPH20, which facilitates the administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and enhanced resorption of radiopaque agents in subcutaneous urography. The company also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20....
-
Company Insights
Innovation and Patenting activity of Halozyme Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Halozyme Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Daratumumab + Hyaluronidase (human Recombinant)) in Peripheral Neuropathy (Sensory Neuropathy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (human Recombinant)) in Peripheral Neuropathy (Sensory Neuropathy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Daratumumab + Hyaluronidase (human Recombinant)) in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Daratumumab + Hyaluronidase (human Recombinant)) in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (human Recombinant)) in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Daratumumab + Hyaluronidase (human Recombinant)) in Alzheimer's Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Daratumumab + Hyaluronidase (human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Daratumumab +...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Sustained Release Injectable...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Daratumumab + Hyaluronidase (Human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Daratumumab + Hyaluronidase (Human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Daratumumab + Hyaluronidase...
-
Company Profile
Halozyme Therapeutics Inc – Company Profile
Halozyme Therapeutics Inc (Halozyme) is a biotechnology company that develops and commercializes novel recombinant human enzymes for enhancing the delivery of biologics and drugs. The company’s marketed product, Hylenex, is a branded recombinant formulation of rHuPH20, which facilitates the administration of subcutaneous fluid with improved hydration, absorption and dispersion of other injected drugs and enhanced resorption of radiopaque agents in subcutaneous urography. The company also offers proprietary Enhanze, a drug-delivery technology built on its patented recombinant human hyaluronidase enzyme, rHuPH20....
Add to Basket -
Company Profile
Antares Pharma Inc – Company Profile
Antares Pharma Inc (Antares Pharma), a subsidiary of Halozyme Therapeutics Inc, is a specialty pharmaceutical company engaged in the development, manufacturing, and commercialization of pharmaceutical products and technologies. The company’s portfolio encompasses around novel therapeutic products for therapy areas related to polyarticular juvenile idiopathic arthritis, severe rheumatoid arthritis, severe recalcitrant psoriasis, migraine and cluster headache. It also develops products to reduce the risk of preterm birth in pregnant women. It caters its subcutaneous injection technology platforms to both generic and...
Add to Basket -
Track & Monitor
Innovation in Pharmaceuticals: Glycoside hydrolase-based drug compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...